Cancer heterogeneity remains a significant challenge for effective cancer treatments. Altered energetics is one of the hallmarks of cancer and influences tumor growth and drug resistance. Studies have shown that heterogeneity exists within the metabolic profile of tumors, and personalized-combination therapy with relevant metabolic interventions could improve patient response. Metabolomic studies are identifying novel biomarkers and therapeutic targets that have improved treatment response. The spatial location of elements in the tumor microenvironment are becoming increasingly important for understanding disease progression. The evolution of spatial metabolomics analysis now allows scientists to deeply understand how metabolite distribution contributes to cancer biology. Recently, these techniques have spatially resolved metabolite distribution to a subcellular level. It has been proposed that metabolite mapping could improve patient outcomes by improving precision medicine, enabling earlier diagnosis and intraoperatively identifying tumor margins. This review will discuss how altered metabolic pathways contribute to cancer progression and drug resistance and will explore the current capabilities of spatial metabolomics technologies and how these could be integrated into clinical practice to improve patient outcomes.

中文翻译：

---

肿瘤微环境界面的代谢组学：解码细胞对话

癌症异质性仍然是有效癌症治疗的重大挑战。能量学改变是癌症的标志之一，影响肿瘤生长和耐药性。研究表明，肿瘤的代谢特征存在异质性，个性化组合治疗与相关代谢干预措施可以改善患者的反应。代谢组学研究正在确定可改善治疗反应的新型生物标志物和治疗靶点。肿瘤微环境中元素的空间位置对于理解疾病进展变得越来越重要。空间代谢组学分析的发展现在使科学家能够深入了解代谢物分布如何对癌症生物学做出贡献。最近，这些技术已将代谢物分布空间解析到亚细胞水平。有人提出，代谢图谱可以通过改善精准医疗、实现早期诊断和术中识别肿瘤边缘来改善患者的治疗结果。这篇综述将讨论代谢途径的改变如何导致癌症进展和耐药性，并将探讨空间代谢组学技术的当前能力以及如何将这些技术整合到临床实践中以改善患者的治疗结果。